Two significant clinical successes emerged this week: Novartis achieved back-to-back Phase III wins for ianalumab in Sjögren’s disease and primary immune thrombocytopenia, demonstrating promising efficacy in autoimmune conditions. Simultaneously, Bayer’s new KRAS G12D inhibitor deal with Kumquat biosciences signals progress against historically ‘undruggable’ cancer drivers. These developments underscore momentum in immunotherapies and precision oncology for challenging diseases.